Technology
Health
Pharmaceutical
Biohaven Pharmaceutical
$50.859876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$50.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$2.44 (-4.58%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell BHVN and other stocks, options, ETFs, and crypto commission-free!
About
Biohaven Pharmaceutical Holding Company Ltd., also called Biohaven Pharmaceutical, is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. Read More The company was founded in September 2013 and is headquartered in New Haven, CT.
CEO
Employees
63
Headquarters
New Haven, Connecticut
Founded
2013
Market Cap
2.36B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
470.83K
High Today
$53.66
Low Today
$50.60
Open Price
$52.86
Volume
121.23K
52 Week High
$53.66
52 Week Low
$16.50
Collections
Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Research And Development
2017 IPO
US
News
PR NewswireMar 13
Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
NEW HAVEN, Conn., March 13, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, today announced that the Company concluded its pre-New Drug Application ("NDA") meetings with the U.S. Food and Drug Administration ("FDA") for rimegepant Zydis® ODT (orally dissolving tablet) and tablet formulations fo...
BenzingaFeb 28
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results
NEW HAVEN, Conn., Feb. 28, 2019 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting central nervous system diseases, including rare neurological disorders, today reported financial results for the fourth quarter and year ended December 31, 2018, and provided a review of recent accomplishments and anticipated upcoming milestones. "In 2018, we achieved significant progress a...
Price Paid on Robinhood
13% Higher
Right Now
52 Week Low
$16.50
Average Price Paid
$44.95
52 Week High
$53.66
Earnings
-$2.32
-$1.75
-$1.18
-$0.61
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 14, After Hours